Tyrosine kinase inhibitors and human epidermal growth factor receptor-2 positive breast cancer  

作　　者：Aya Abunada Zaid Sirhan Anita Thyagarajan Ravi P Sahu 

机构地区：[1]Department of Pharmacy,Sidra Medicine,Doha 0000,Qatar [2]Department of Pharmacology and Toxicology,Boonshoft School of Medicine Wright State University,Dayton,OH 45435,United States

出　　处：《World Journal of Clinical Oncology》2023年第5期198-202,共5页世界临床肿瘤学杂志（英文版）

基　　金：Supported by the Elsa U.Pardee Foundation Grant,No.671432(to Sahu RP);NIH R21 Grant,No.ES033806(to Sahu RP).

摘　　要：The body of evidence investigating human epidermal growth factor receptor-2(HER2)directed therapy in patients with breast cancer(BC)has been growing within the last decade.Recently,the use of tyrosine kinase inhibitors(TKIs)has been of particular interest in the treatment of human malignancies.This literature commentary is intended to highlight the most recent findings associated with the widely-studied TKI agents and their clinical significance in improving the outcomes of HER2 positive BC.

关 键 词：Human epidermal growth factor receptor-2 positive breast cancer Tyrosine kinase inhibitors LAPATINIB Pyrotinib Tucatinib TRASTUZUMAB 

分 类 号：R737.9[医药卫生—肿瘤]